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ABSTRACT
Carbonic anhydrase (CA) IX is a hypoxia inducible enzyme that is highly expressed in solid tumours.
Therefore, it has been considered as an anticancer target using specific chemical inhibitors. The nitroimida-
zoles DTP338 and DTP348 have been shown to inhibit CA IX in nanomolar range in vitro and reduce extra-
cellular acidification in hypoxia, and impair tumour growth. We screened these compounds for toxicity
using zebrafish embryos and measured their in vivo effects on human CA IX in Xenopus oocytes. In the
toxicity screening, the LD50 for both compounds was 3.5mM. Neither compound showed apparent toxicity
below 300mM concentration. Above this concentration, both compounds altered the movement of zebra-
fish larvae. The IC50 was 0.14±0.02mM for DTP338 and 19.26±1.97mM for DTP348, suggesting that these
compounds efficiently inhibit CA IX in vivo. Our results suggest that these compounds can be developed
as drugs for cancer therapy.
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Carbonic anhydrase (CA) IX is a zinc-containing metalloenzyme
that efficiently catalyses the reversible hydration of CO2 to H
þ and
HCO3
 1–3. CA IX is highly expressed in hypoxic tumours where it is
involved in the regulation of acid-base balance and cell-to-cell
adhesion4–9. In normal tissues, CA IX shows limited expression in
the gastric mucosa, gall bladder, bile ducts and small intestine8,10.
The high expression of CA IX in hypoxic tumours and the associ-
ated molecular events contribute to metastatic phenotype and
resistance to anticancer drugs, promoting the survival of cancer
cells as well as tumour progression11. CA IX is an important con-
tributor to the tumour microenvironment where it participates in
ion transport across the plasma membrane. The enzyme thus pro-
tects the tumour cells from intracellular acidosis by facilitating the
export of acidic metabolic products5,8.
Hypoxic tumours do not respond well to general chemotherapy
and radiotherapy in many cases8,9,12. Inhibition of CA IX is consid-
ered a promising adjunct therapeutic option as it has been shown
to sensitize hypoxic tumours to existing therapies13. Like the other
a-CAs, CA IX can be inhibited by anions, sulfonamides, sulfamides
and sulfamates14. Recently, many inhibitors have been identified
that inhibit CA IX in low nanomolar quantities2,15. Binding of some
inhibitors to CAs has been investigated using X-ray crystallog-
raphy, and it has been shown that they are membrane
impermeable16,17.
In the pursuit of developing novel methods for the treatment
of hypoxic tumours, we designed and synthesized a series of
nitroimidazoles as radio/chemosensitizing agents, targeting the
tumour-associated CA IX18. Among these compounds are two
nitroimidazoles, DTP338 and DTP348 (Figure 1), that were synthe-
sized by incorporating a sulfamate or sulfamide and moiety as
zinc-binding groups (ZBGs) respectively, as described earlier by
our group19,20. The in vitro inhibition kinetics showed that both of
these compounds inhibit the activity of human CA IX in nanomo-
lar quantities18. Further studies involving cancer cells showed that
the inhibitors reduced hypoxia-induced extracellular acidosis in
two different cell lines18. The lead compound DTP348 sensitized
the CA IX containing tumours when treated in combination with
doxorubicin18.
Before the newly synthesized compounds are taken into clinical
trials and developed further as therapeutic agents, it is important
to characterize them for safety and toxicity preclinically using cell
and animal models. In the past, nitroimidazoles have shown sig-
nificant clinical toxicity21,22. However, to date, none of the present
agents have been screened for toxicity and safety using an animal
model, and no in vivo inhibition profiles of nitroimidazoles against
human CA IX have been demonstrated using an eukaryotic
cell model.
In the recent past, zebrafish has emerged as a vertebrate ani-
mal model for determining drug-induced toxicity in a preclinical
drug development process23–26. The zebrafish provides many
advantages compared to the other vertebrate model organisms.
These include high fecundity, rapid development ex utero, and the
ease of maintaining large numbers in a small space.
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Administration of drug is easy as the embryos absorb the drug
molecules from the water through their skin and gills24. Similarly,
the Xenopus laevis has been widely used as an animal model in
molecular and physiological research, especially with heterolo-
gously expressed proteins in the oocytes27. The oocytes have
advantages, such as easy manipulation due to the large cell size
(1.1–1.33mm), convenient laboratory maintenance, and the
oocytes can be obtained in large numbers27. The results of electro-
physiological measurements obtained in Xenopus oocytes are not
affected by the activity of endogenous proteins, making the
oocytes versatile tools for biochemical applications. Similarly,
native Xenopus oocytes contain undetectably low level of CA activ-
ity28. Therefore, the injections of cRNA coding for human CA iso-
zyme into oocytes allow the expression of the target CA and
investigation of CA inhibition in the live biological system. The
inhibitory properties of ethoxzolamide (EZA), a membrane-perme-
able and nonselective sulfonamide CA inhibitor, against CA II, CA
IV, and CA IX have been reported in oocytes29–31. Thus, Xenopus
oocyte is a promising animal model to study the roles of CAs and
characterize the affinity and selectivity of human CA inhibitors in
the living eukaryotic cell with fully matured target CA isozyme.
In the present study, we used zebrafish as a vertebrate model
organism and evaluated the safety and toxicity of the two nitroi-
midazole-based CA inhibitors DTP338 and DTP348, studied the
inhibitory properties of these compounds in vitro using
Mycobacterium marinum and studied their efficiency for inhibition
of human CA IX in vivo in Xenopus oocytes. Figure 1 shows the
structures of the inhibitors that were used in this study.
Materials and methods
Inhibitors
The two nitroimidazoles DTP338 and DTP348 (Figure 1(A,B)) used
in the study were synthesized by some of our group and in vitro
inhibition studies against several human CAs have been described
previously18,19. Nitroimidazole DTP338, a sulfamate analogue was
prepared from starting material, metronidazole, using a direct sul-
famoylation procedure as described earlier20. The nitroimidazole
sulfamide DTP348, and was obtained by a procedure reported ear-
lier18,19. Both nitroimidazoles were investigated in vitro as specific
inhibitors of human CA IX enzyme and found to inhibit the
enzyme in sub-nanomolar range18. The compounds DTP338 and
DTP348 were dissolved in dimethyl sulfoxide (DMSO) to prepare
100mM stock solutions. Before exposing the 1 day post fertiliza-
tion (dpf) embryos to the different dilutions of the compounds, a
series of dilutions of each compound were prepared using embry-
onic medium [5.0mM NaCl, 0.17mM KCl, 0.33mM CaCl2, 0.33mM
MgSO4, and 0.1% w/v Methylene Blue (Sigma-Aldrich, Germany)].
Maintenance of zebrafish
Wild type zebrafish of the AB strain were maintained at 28.5 C in
an incubator, as described previously25. The 1–2 hour post fertiliza-
tion (hpf) embryos were rinsed with embryonic medium and kept
in the incubator at 28.5 C overnight. The toxicity experiments
were performed using the fish that were 24 hpf. All the zebrafish
experiments were performed at the zebrafish core facility,
University of Tampere, Finland.
Ethical statement
The zebrafish core facility at the University of Tampere has an
establishment authorization granted by the National Animal
Experiment Board (ESAVI/7975/04.10.05/2016). All experiments
using zebrafish were performed according to the Provincial
Government of Eastern Finland, Social and Health Department of
Tampere Regional Service Unit protocol # LSLH-2007–7254/Ym-23.
Care was taken to ameliorate suffering by euthanizing the zebra-
fish by prolonged immersion in a petri dish containing an over-
dose of Tricaine (Sigma-Aldrich, St. Louis, MO, USA) before fixing
in buffered formaldehyde for histochemical analysis.
Toxicological studies of nitroimidazole compounds DTP338
and DTP348
Determination of LD50
For determining the LD50 values of the DTP338 and DTP348 com-
pounds we used eight groups of zebrafish for each concentration
of the compound, with sixty 1 dpf zebrafish per group. In each
group, the larvae were exposed to different concentrations of the
compound that ranged from 10 mM to 3.5mM. The dose response
curve (DRC) was calculated using DRM of the DRC R package32. As
control groups, we used an equal number of wild type larvae not
treated with any drug or compound and 1% DMSO treated larvae.
The experiments were carried out in 24-well plates (Corning V R
Costar V R cell culture plates). In each well, we placed ten 1 dpf
embryos in 1ml of embryonic medium containing either a diluted
inhibitor, 1% DMSO diluted in embryonic medium or embryonic
medium with no inhibitor. A minimum of three sets of experi-
ments were carried out for each inhibitor. Survival of the embryos
was checked every 24 h until five days after the first exposure.
Phenotypic analysis of control and inhibitor-treated larvae
To assess the effect of inhibitors on the embryos after five days of
exposure to the inhibitors, we analysed seven observable pheno-
typic parameters: (1) movement pattern, (2) yolk sack utilization,
(3) hatching, (4) heartbeat, (5) body shape, (6) swim bladder devel-
opment and (7) oedema using a stereo microscope and recorded
the observations for each group. The images of the developing
larvae were taken using a Lumar V1.12 fluorescence microscope
attached to a camera (Carl Zeiss MicroImaging GmbH, G€ottingen,
Germany). The images were analysed with AxioVision software
versions 4.7 and 4.8.
Swim pattern analysis
The movement of the zebrafish larvae was tracked from day 3 of
exposure to the nitroimidazole inhibitors. Similarly, detailed ana-
lysis of the swim pattern of the larvae was performed at the end
of day 5 after exposure to the inhibitors. For the analysis of move-
ment pattern, the zebrafish larvae were placed in 35 15mm Petri
dish containing embryonic medium, and the larvae were allowed
(A) (B)
Figure 1. Chemical structures of the compounds used in the study. (A) The nitro-
imidazole DTP338 (compound 9 in the original study)18 inhibits human CA IX
showed inhibition constant Ki 8.3 nM in vitro18. (B) The nitroimidazole DTP348
(compound 7 in original study) inhibitions human of CA IX in vitro at the concen-
tration of 20.4 nM18.
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to settle in the Petri dish for 1min. The movement of the zebrafish
larvae was observed under the microscope for 1min. The images
of the moving zebrafish larvae were taken using a stereomicro-
scope, and the swim patterns were compared with the control
group zebrafish larvae that were not treated with any inhibitor
and the larvae treated with 1% DMSO.
Histochemical analysis
At the end of five days of inhibitor treatment, representative lar-
vae from each group were collected for histological examination.
The histological analyses were done to check the effect of inhibi-
tors on internal tissues of the larvae that were treated with differ-
ent concentrations of nitroimidazole compounds, and the results
were compared to the control group larvae. At the end of the
experiments the zebrafish larvae were washed with phosphate-
buffered saline (PBS) and excess amounts of Tricaine were added
to the wells to anesthetize the larvae. The anesthetized larvae
were transferred to a 1.5ml tube and fixed in buffered formalde-
hyde (formaldehyde solution 4%, pH 6.9) in PBS for 3 h at room
temperature or overnight at 4 C. After the fixation, the larvae
were transferred to 70% ethanol and stored at 4 C before being
embedded in paraffin. The paraffin embedded samples were sec-
tioned into 5mm slices for histochemical staining. The fixed sec-
tions containing samples were deparaffinized in xylene, rehydrated
in an alcohol series, and stained with Mayer’s Hematoxylin and
Eosin Y (both from Sigma-Aldrich). After dehydration, the slides
were mounted with EntellanVR Neu (Merck; Darmstadt, Germany).
The slides containing the tissues were examined for the presence
of pathological changes in the tissues of the larvae exposed to the
inhibitors and photographed using a Nikon Microphot microscope
(Nikon Microphot-FXA, Japan). All the procedures were carried out
at room temperature unless stated otherwise.
Determination of minimal inhibitory concentration in in vitro cul-
tures of Mycobacterium marinum
We determined the minimal inhibitory concentration (MIC) of the
inhibitors according to the protocol by Hall et al.33 with some
modifications. In short, wild type M. marinum (ATCC 927) was
grown on Middlebrook 7H10 agar plates (BD) for six days at
þ29 C. Bacterial mass was scraped from the plate and transferred
into PBS pH 7.4 containing 0.2% Tween 80 (Sigma-Aldrich) to
obtain an OD600 of 0.08–0.100. 200ml of this bacterial suspension
was mixed with 11ml of Middlebrook 7H9 Broth OADC Becton
Dickinson (BD) (no tween, no glycerol) by vortexing. The bacterial
concentration was determined by plating on 7H10 agar (BD) and
purity by plating on LB agar (Sigma-Aldrich). Plates were incu-
bated for six days at þ29 C. The bacterial concentration was
between 1.4 105 and 4.7 105 colony forming units (cfu)/ml.
50ml of this bacterial suspension was pipetted per well onto ster-
ile, clear 96-well tissue culture treated plates (Corning Costar from
Sigma-Aldrich). The filter sterilized CA inhibitors dissolved in
Middlebrook 7H9 Broth OADC (no tween, no glycerol) were added
on top of bacteria in a volume of 50 ml. A concentration range of
200 mM–3mM using a 10-fold dilution series was tested in two
separate experiments on 6 replicate wells. The lids were sealed
onto the plates with parafilm and the cultures were incubated at
þ28.5 C for five days. The result was determined by assessing the
turbidity of the cultures both by visual inspection and by an
OD600 measurement using Perkin Elmer Envision multi-reader
scan measurement. Five horizontal and five vertical points
0.72mm apart were measured from each well. The sum of the
readings was calculated for each sample. The background signal
from wells containing medium only was subtracted from
all values.
Constructs, oocytes and injections of cRNA
Human CA IX cDNA was kindly provided by Dr. Robert McKenna,
University of Florida, Gainesville, and cloned into the oocyte
expression vector pGEM-He-Juel, which contains the 50 and the 30
untranscribed regions of the Xenopus b-globin flanking the mul-
tiple cloning site. Plasmid DNA was transcribed in vitro with T7
RNA-Polymerase (mMessage mMachine, Ambion Inc., Austin, USA)
as described earlier27,34. Xenopus laevis females were purchased
from the Radboud University, Nijmegen, Netherlands. Segments of
ovarian lobules were surgically removed under sterile conditions
from frogs anesthetized with 1 g/l of ethyl 3-aminobenzoate meth-
anesulfonate (MS-222, Sigma-Aldrich), and rendered hypothermic.
The procedure was approved by the Nieders€achsisches Landesamt
f€ur Verbraucherschutz und Lebensmittelsicherheit, Oldenburg,
Germany (33.19-42502-05-17A113). As described earlier27,34,
oocytes were singularized by collagenase (Collagenase A, Roche,
Mannheim, Germany) treatment in Ca2þ-free oocyte saline (pH 7.8)
at 28 C for 2 h. The singularized oocytes were left overnight in an
incubator at 18 C in Ca2þ-containing oocyte saline (pH 7.8) to
recover. Oocytes of the stages V and VI were injected with 5 ng of
cRNA coding for human CA IX. The oocyte saline had the follow-
ing composition: 82.5mM NaCl, 2.5mM KCl, 1mM CaCl2, 1mM
MgCl2, 1mM Na2HPO4, 5mM HEPES; titrated with NaOH to the
desired pH.
Determination of CA IX activity in Xenopus oocytes
Catalytic activity of CA IX in Xenopus oocytes was determined by
monitoring the 18O depletion of doubly labelled 13C18O2 through
several hydration and dehydration steps of CO2 and HCO3
 at
23 C as previously described35,36. The reaction sequence of 18O
loss from 13C18O18O (m/z¼ 49) over the intermediate product
13C18O16O (m/z¼ 47) and the end product 13C16O16O (m/z¼ 45)
was monitored with a quadrupole mass spectrometer (OmniStar
GSD 320; Pfeiffer Vacuum, Asslar, Germany). The relative 18O
enrichment was calculated from the measured 45, 47, and 49
abundances as a function of time according to: log enrich-
ment¼ log [49 100/(49þ 47þ 45)]. For calculation of CA IX activ-
ity, the rate of 18O degradation was obtained from the linear slope
of the log enrichment over the time, using the spreadsheet analy-
sing software OriginPro 8.6 (OriginLab Corporation, Northampton,
USA). The rate was compared with the corresponding rate of the
non-catalysed reaction. Enzyme activity in units was calculated
from these two values as defined by37. From this definition, one
unit corresponds to 100% stimulation of the non-catalysed 18O
depletion of doubly labelled 13C18O2. The measurements were
carried out in oocyte saline at pH 7.0. For every measurement the
non-catalysed reaction was determined for 6min before adding
lysate from 20 CA IX-expressing oocytes to the cuvette. After the
catalysed reaction was measured for 6min, inhibitor was added
stepwise in increasing concentration every 4min. Catalytic activity
in the presence of inhibitor was normalized to the catalyzed reac-
tion in the absence of inhibitor for every measurement. IC50 values
were calculated from a Hill1 fit using OriginPro 8.6.
Statistical analysis
The GraphPad Prism software (5.02) was used to perform statistical
analysis. For statistical analysis of the toxicity parameters, a
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two-tailed Fisher’s test was used and p values below 0.05 were
considered significant.
Results
Determination of LD50 values of DTP338 and DTP348
The toxic effects of both DTP338 and DTP348 compounds were
dose-dependent in the zebrafish embryos that were exposed to
either inhibitor for five days. Neither inhibitor showed any signifi-
cant mortality up to 1.5mM concentration at the end of five days
of exposure to the inhibitors. The mortality of zebrafish embryos
was dose-dependent the concentration required for the mortality
of 50% of larvae at the end of five days of expose to the inhibitors
was 3.5mM for both inhibitors. The LD50 values of both inhibitors
are shown in Figure 2.
Phenotypic defects in the zebrafish larvae
To assess the adverse effects of the nitroimidazole derivatives on
the developing zebrafish larvae we studied the observable pheno-
typic parameters of the larvae that were exposed to different con-
centrations of the inhibitors and compared with the zebrafish
larvae that were exposed to 1% DMSO. Figure 3 shows images of
representative larvae treated with 100–500 mM concentrations of
the inhibitors and the images of larvae from control groups.
Neither inhibitors showed any significant adverse effects on the
observable parameters, such as survival, hatching, oedema, heart-
beat, body shape, swim bladder development, and yolk sac utiliza-
tion at the concentration of 1.5mM or below during the
embryonic development, nor did they show any abnormalities at
the end of five days of exposure compared to the embryos treated
with 1% DMSO. Figure 4(A–C) shows the effects of inhibitors on
the studied parameters and dose dependent mortality of
the larvae.
The zebrafish treated with inhibitors for five days showed ataxic
movement pattern
The swim pattern of the zebrafish larvae was one of the parame-
ters analysed for determination of toxic effects of the inhibitors.
The analysis of the swim pattern showed no abnormality until
4 dpf. However, at the end of five days the larvae exposed to
either DTP338 or DTP348 showed various degrees of ataxic move-
ment patterns at the concentrations ranging from 100 to 1500 mM
(Figure 5(D)). Further analysis of the swim pattern of the zebrafish
larvae treated with 10–500mM concentrations of the inhibitors
showed significantly abnormal movement in the larvae treated
with 300mM or above concentration of DTP338 (p> 0.001). The
lowest dose of DTP338 at which the zebrafish larvae showed some
tendency of abnormal swimming was 200 mM. This difference of
the swim pattern was not statistically significant compared to the
control group embryos (Figure 5(D)). Interestingly, the zebrafish
larvae treated with DTP348 showed considerably abnormal swim
pattern even at 100 and 200mM concentrations (p> 0.036) as
shown in Figure 5(D). When compared with the control group lar-
vae, the inhibitor treated larvae moved slowly and had increased
turning angle with a difficulty in balancing the body when moving
forward (Figure 5(A–C)).
The histochemical analyses showed no effect on
tissue morphology
We studied the effect of these inhibitors on tissues by analysing
thin sections of the zebrafish larvae stained with Eosin and
Hematoxylin (H & E). The H & E stained sections of the inhibitor-
treated zebrafish larvae were compared with the control group
fish that were treated with 1% DMSO or not treated with any
inhibitor. The microscopic examination of the sections did not
reveal any damage to the tissues of the developing zebrafish lar-
vae at the analysed concentrations of nitroimidazole inhibitors.
The representative images of the fish that were analysed histo-
chemically are shown in Figure 6.
Determination of the minimal inhibitory concentration of
nitroimidazole inhibitors
A study has shown that Ethoxzolamide, a general inhibitor of
human CAs inhibits the PhoPR regulon, a two-component regula-
tory system in Mycobacterium tuberculosis, and prevents the forma-
tion of biofilms in Nontuberculous mycobacteria (NTM)25,38.
Therefore, we wanted to test if the nitroimidazole compounds
DTP338 or DTP348 show any antibacterial effects in a zebrafish
model. For this purpose, we utilized a well-characterized infection
model where the fish are infected with M. marinum, a natural TB
causing pathogen of zebrafish. First, we performed standard MIC
Figure 2. The LD50 determination of nitroimidazole inhibitors. The LD50 dose for the CA IX inhibitors DTP338 and DTP348 was determined based on cumulative mortal-
ity of the zebrafish larvae at the end of five days after the exposure of embryos to different concentration of the inhibitors. The LD50 doses for both the DTP338 and
DTP348 compounds were in the range of 3.5mM concentration (A and B). The LD50 were determined after three independent experiments with similar experimental
conditions (n 180).
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experiments for both nitroimidazoles using liquid cultures of
M. marinum on 96 well plates. In the MIC tests, we inspected
growth of bacteria visually at the end of six days of incubation
with different concentrations of the inhibitors. In addition, we
measured the optical density of the cultures to obtain the growth
curve of the bacteria. The experiments carried out twice with
these inhibitors did not show any effects on the growth of M.
marinum even at the concentrations as high as 2.5mM. The MIC
tests suggested that the nitroimidazole inhibitors do not inhibit
the growth of bacteria and hence these inhibitors are not antibac-
terial (data not shown).
In vivo inhibition of human CA IX activity in Xenopus oocytes
The nitroimidazole inhibitors DTP338 and DTP348 inhibit the activ-
ity of recombinant human CA IX in vitro in nanomolar concentra-
tions (Ki of 20.4 nM for DTP338 and Ki of 8.3 nM for DTP348) and
are considered potential drugs for cancer therapy18. In addition to
safety studies using zebrafish as a vertebrate model, we also
aimed to determine the efficiency of these inhibitors for in vivo
inhibition of CA activity. We used Xenopus oocytes as an in vivo
model organism to determine the IC50 doses of the nitroimidazole
compounds. The inhibition of the heterologously expressed
human CA IX by DTP338 and DTP348 was monitored with mass
spectrometry (MS). Among these two CA IX inhibitors, DTP338
inhibited the enzyme activity more effectively in the oocytes and
the IC50 value for inhibition of CA IX was 140 nM (Figure 7(A)). The
IC50 value of DTP348 (IC50 19mM) was higher compared to DTP338
(Figure 7(B)). Therefore, the nitroimidazole inhibitor DTP338 is
potentially a better inhibitor of human CA IX compared to
DTP348, at least in vivo in Xenopus oocyte model system.
Discussion
The purpose of the study was to evaluate the safety and toxicity
of novel nitroimidazole derivatives DTP338 and DTP348, and sub-
sequently determine the in vivo inhibitory properties of these
inhibitors against human CA IX in Xenopus oocytes. This is import-
ant in development of these inhibitors both as anticancer agents
for the treatment of hypoxic tumours and as tumour sensitizers
before treatment with existing treatment methods. Nitroimidazole
inhibitors DTP338 and DTP348 belong to a structurally distinct
class of CA inhibitors that have been designed and synthesized
recently18. These compounds inhibit extracellular tumour acidifica-
tion at least in two cell lines overexpressing CA IX, namely the
colorectal HT-29 and the cervical HeLa carcinoma cell lines18.
In vitro and in vivo studies have demonstrated that these inhibitors
are potential drug candidates against human CA IX in the
Figure 3. Phenotypic images zebrafish embryos in control and nitroimidazole inhibitor treated groups. Developmental images of 1–5 dpf zebrafish embryos exposed to
different concentrations of DTP338 and DTP348. (A) The images of control group (not treated with inhibitors) and 1% DMSO treated zebrafish larvae show normal
development. (B) The zebrafish larvae treated with different concentrations (100–500lM) of DTP338. (C) The images of zebrafish larvae exposed to different concentra-
tions (100–500lM) of DTP348. The embryos exposed up to 500lM concentrations show no apparent phenotypic abnormalities at the end of 5 after exposure to the
drugs and had normal embryonic development.
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treatment of hypoxic tumours18,39. The lead compound of our
study DTP348, that was used for sensitizing tumours in combin-
ation with doxorubicin in mice, was previously assessed for toxicity
based only on the assessment of body weight measurements18,39.
Interestingly, studies in the past have shown that the nitroimida-
zole compounds used for sensitizing tumours are highly toxic and
unacceptable for use in therapy, even though they achieved thera-
peutic efficacy21,22.
Potential anti-cancer drugs need to be evaluated thoroughly
for toxicity and safety prior to any tests in humans. To evaluate
toxicity and doses required for inhibition of CA IX in vivo, we used
both zebrafish larvae and Xenopus oocyte models, respectively.
Zebrafish have been widely used for acute and chronic toxicity
testing as well as for studying developmental toxicity40. Zebrafish
embryos develop ex utero and the chemical compounds can be
easily added to the fish tank water, making it a highly feasible
model for studying many aspects of toxicity. Developing embryos
are more easily affected by chemical compounds than adult fish
making assays with embryos more sensitive40,41. Xenopus oocytes
have been used for in vivo inhibition studies of CAs and for the
determination of IC50 doses for the inhibition of human CA IX
42.
For the evaluation of toxicity of the nitroimidazoles we used
1–5 dpf zebrafish and studied the effects of these inhibitors on
mortality, hatching rate, oedema, heartbeat, swim bladder devel-
opment, yolk sack and movement pattern. In addition, we
studied histopathology of the tissues to investigate the toxic
effect of the compounds on the tissues during embryonic
development.
The toxicity screening of the inhibitors showed that the LD50
doses of both DTP338 and DTP348 were in the range of 3.5mM.
The studies also showed that the inhibitors did not exhibit any
significant effects on the observable parameters namely hatching,
yolk sac utilization, oedema, heartbeat, swim bladder develop-
ment, and mortality when assessed at 1.5mM concentration after
Figure 4. Effect of nitroimidazole inhibitors on phenotypic parameters of the 5 dpf zebrafish embryos. Panel A and B show bar graphs of observable phenotypic
parameters (1) swim bladder, (2) body shape, (3) yolk sack, (4) heartbeat and (5) hatching and zebrafish larvae treated with different concentrations of DTP338 (A) and
DTP348 (B). In the inhibitor treated groups of both the compounds, the parameters, swim bladder development, body shape, utilization of yolk sack, heartbeat and
hatching showed no significant difference compared control group zebrafish larvae. At the end of five days after exposure to inhibitors the zebrafish larvae showed a
significant difference in the swim pattern compared to control group larvae. (C) The bar graph panel shows the percent survival of the zebrafish larvae in inhibitor
treated group and control group treated with 1% DMSO. For each concentration, n 120. p< 0.05 by two-tailed Fisher’s test.
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five days of exposure to the inhibitors. Histochemical staining of
the whole zebrafish sections showed no apparent damage to the
tissues in the larvae exposed to inhibitor concentrations below
2mM (Figure 6(C–F)).
Interestingly, embryos exposed to either of the inhibitors at a
concentration of 100mM or above generally showed mild to sig-
nificant ataxic swim pattern (abnormal movement), which is
likely caused by neurotoxicity, at the end of five days exposure.
This is similar to the swim pattern of fish which have the CA8
gene knocked down, a gene associated with motor coordination
function in human, mice and zebrafish43. Apart from ataxic
swim pattern none of the fish showed significant defects in
morphologic phenotype. However, further studies using molecu-
lar and electron microscopic techniques could reveal the precise
changes in the brain. Based on the results of the present study,
it is important to consider the dose of the inhibitors critical
either for sensitizing the tumours or for the treatment of the
solid tumours.
The IC50 value of DTP338 for human CA IX expressed in
Xenopus oocytes was 140 nM, while it was 19.26 mM in the case of
DTP348. The current in vivo inhibition results contrast with the
results of in vitro inhibition study reported earlier18. These current
results suggest that the requirement of therapeutic doses for the
inhibition of CA IX in vivo in tumours may be higher than
suggested by in vitro studies, and need to be carefully considered
when deciding the therapeutic doses for the treatment of cancers.
The obtained values will also help to define more precisely the
concentrations for further pre-clinical testing in rodent models.
The nitroimidazole compounds have been designed and syn-
thesized for inhibiting human CA IX and in vitro inhibition analysis
using human recombinant CA IX previously showed that these
inhibitors inhibit hCA IX in sub-nanomolar quantities18. We
hypothesized that, if these inhibitors are not toxic and inhibit only
human CAs, they should not inhibit the growth of the M. marinum
bacteria, neither due to toxicity nor via inhibition of b-CAs critical
for their survival. In our earlier study, the growth of the mycobac-
terium could be inhibited in vitro in culture and in vivo in zebra-
fish using dithiocarbamates, the known inhibitors of mycobacterial
b-CAs25. The MIC tests of the current study showed that these
nitroimidazole compounds do not inhibit the growth of the bac-
terium even at concentrations as high as 2.5mM, suggesting that
these inhibitors are not toxic to the bacterium, neither directly nor
through the inhibition of b-CAs.
In conclusion, this study showed that the nitroimidazole inhibi-
tors DTP338 and DTP348 exhibit no toxicity at or below 300mM
concentrations during the embryonic development of zebrafish,
and hence are probably safe at lower concentrations for use as
anticancer drugs. Although these inhibitors inhibit the activity of
Figure 5. Ataxic swim pattern of the zebrafish larvae. (A) Zebrafish larvae (5 dpf) showing normal swim pattern. (B) The zebrafish larvae treated with 300 lM DTP338
show wobbling movement along the path at the end of five days after exposure to the inhibitor. (C) The zebrafish larvae treated with 300lM DTP348 also show wob-
bling movement along the path at the end of fier days after exposure to the inhibitor. The swim pattern of the larvae treated with inhibitors showed difficulty in bal-
ancing the body while moving forward with a curve in the body (arrow heads). (D) Shows the bar graph of swim pattern treated with different concentration of
nitroimidazoles.
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human CA IX in vitro at low nanomolar concentrations, the con-
centration required for the inhibition of human CA IX in vivo is
low micromolar. The observed discrepancy between the in vitro
and in vivo results is interesting, indeed, and there might be sev-
eral potential explanations for this difference. Other proteins may
interfere with inhibitor binding in vivo and thus change the phar-
macokinetic properties of the inhibitors. On the other hand, the
chemical stability of the inhibitor may be affected in vivo due to
the presence of multiple biological and chemical factors.
Nevertheless, our result suggests that the required concentration
for inhibition of CA IX in human cells may be at micromolar range.
Because the zebrafish studies suggested some neurotoxicity at
higher concentration levels, further preclinical in vivo studies are
warranted to adjust optimal inhibitor concentrations before enter-
ing any clinical trial.
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